Cargando…
Ligand-based quantitative structural assessments of SARS-CoV-2 3CL(pro) inhibitors: An analysis in light of structure-based multi-molecular modeling evidences
Due to COVID-19, the whole world is undergoing a devastating situation, but treatment with no such drug candidates still has been established exclusively. In that context, 69 diverse chemicals with potential SARS-CoV-2 3CL(pro) inhibitory property were taken into consideration for building different...
Autores principales: | Adhikari, Nilanjan, Banerjee, Suvankar, Baidya, Sandip Kumar, Ghosh, Balaram, Jha, Tarun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627846/ https://www.ncbi.nlm.nih.gov/pubmed/34866654 http://dx.doi.org/10.1016/j.molstruc.2021.132041 |
Ejemplares similares
-
Glycyrrhizin as a promising kryptonite against SARS-CoV-2: Clinical, experimental, and theoretical evidences
por: Banerjee, Suvankar, et al.
Publicado: (2023) -
Structural Insight Into the Viral 3C-Like Protease Inhibitors: Comparative SAR/QSAR Approaches
por: Adhikari, Nilanjan, et al.
Publicado: (2017) -
Identification of potential binders of the main protease 3CL(pro) of the COVID-19 via structure-based ligand design and molecular modeling
por: Macchiagodena, Marina, et al.
Publicado: (2020) -
Structure-based virtual screening against SARS-3CL(pro) to identify novel non-peptidic hits
por: Mukherjee, Prasenjit, et al.
Publicado: (2008) -
Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors
por: Amin, Sk. Abdul, et al.
Publicado: (2021)